Health Care [ 3/12 ] | Biotechnology [ 9/75 ]
NASDAQ | Common Stock
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.
The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials.
It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults.
Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 25 | -1.35 Increased by +26.23% | -0.95 Decreased by -42.11% |
| Aug 19, 25 | -2.14 Increased by +60.88% | -0.93 Decreased by -130.11% |
| May 8, 25 | -1.04 Increased by +85.56% | -0.94 Decreased by -10.64% |
| Mar 27, 25 | -3.68 Increased by +51.96% | -2.93 Decreased by -25.60% |
| Nov 11, 24 | -1.83 Decreased by -510.00% | -2.22 Increased by +17.57% |
| Aug 13, 24 | -5.47 Decreased by -859.65% | -4.92 Decreased by -11.18% |
| May 8, 24 | -7.20 Decreased by -1.96 K% | -12.48 Increased by +42.31% |
| Mar 31, 24 | -7.66 Decreased by -1.77 K% | -4.86 Decreased by -57.61% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -7.34 M Decreased by -77.94% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -4.79 M Decreased by -49.20% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Increased by +100.00% | -3.80 M Decreased by -27.93% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 12.98 B Increased by +N/A% | -6.13 M Decreased by -2.56% | Decreased by -0.05% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -4.13 M Increased by +37.64% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -3.21 M Increased by +19.86% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | -3.85 B Decreased by N/A% | -2.97 M Increased by +35.45% | Increased by +0.08% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.98 M Decreased by -48.47% | Decreased by N/A% Decreased by N/A% |